Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8812762 | 0.98 | ACE2 (0.42) | ACE2FFAR4FFAR1ALDH1A1LMNA | |
| SCHEMBL8811181 | 0.98 | ACE2 (0.42) | ACE2FFAR4FFAR1ALDH1A1LMNA | |
| SCHEMBL8813300 | 0.98 | ACE2 (0.42) | ACE2FFAR4FFAR1ALDH1A1LMNA | |
| SCHEMBL8811537 | 0.93 | ACE2 (0.36) | ACE2CA1ALDH1A1BLMMAPT | |
| SCHEMBL8812359 | 0.84 | BLM (0.41) | ACE2ALDH1A1BLMLMNAMAPT | |
| SCHEMBL8811478 | 0.84 | ACE2 (0.47) | ACE2FFAR4FFAR1CA1ALDH1A1 | |
| SCHEMBL8812086 | 0.84 | BLM (0.41) | ACE2ALDH1A1BLMLMNAMAPT | |
| SCHEMBL50856 | 0.83 | — | — | |
| SCHEMBL7741480 | 0.83 | ACE2 (0.55) | ACE2FFAR4FFAR1ALDH1A1LMNA | |
| SCHEMBL50063 | 0.82 | FFAR4 (0.53) | FFAR4FFAR1ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1095 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0506463-B1 | New compounds, named the \"leustroducsins\" their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-02-28 | — | — | EP | claimed |
| US-5443972-A | Fermentation of Streptomyces | SANKYO COMPANY, LIMITED (JP) | 1995-08-22 | — | — | US | claimed |
| US-5334587-A | For adverse reactions from cancer chemotherapy, infections, cerebral dysfunction or fungal infection | SANKYO COMPANY, LIMITED (JP) | 1994-08-02 | — | — | US | claimed |
| EP-0506463-A2 | New compounds, named the \"leustroducsins\" their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1992-09-30 | — | — | EP | claimed |
| JP-5213758-A | — | — | None | — | — | JP | disclosed |
| JP-5123179-A | — | — | None | — | — | JP | disclosed |
| US-12031079-B2 | Polymerisable LC medium and polymer film with flat optical dispersion | MERCK PATENT GMBH (DE) | 2024-07-09 | — | — | US | disclosed |
| CN-113039659-B | Self-assembled monolayers for electrode modification and devices comprising such self-assembled monolayers | 默克专利有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-105385453-B | Liquid-crystalline medium | 默克专利股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4015598-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2024-05-22 | — | — | EP | disclosed |
| EP-3704176-B1 | ORGANIC SEMICONDUCTING COMPOUNDS | RAYNERGY TEK INC (TW) | 2024-05-15 | — | — | EP | disclosed |
| US-11958819-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| WO-1988007514-A1 | TOLANES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-10-06 | — | — | WO | disclosed |
| WO-1988007523-A1 | ACETYLENE DERIVATIVES AS COMPONENTS OF LIQUID CRYSTAL PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-10-06 | — | — | WO | disclosed |
| EP-0281611-A1 | LIQUID CRYSTAL PHASES FOR ELECTRO-OPTIC DISPLAY ELEMENTS BASED ON THE ECB EFFECT. | MERCK PATENT GMBH (DE) | 1988-09-14 | — | — | EP | disclosed |
| EP-0269963-A2 | Ferroelectric liquid crystals | F. HOFFMANN-LA ROCHE AG (CH) | 1988-06-08 | — | — | EP | disclosed |
| EP-0258340-A1 | SMECTIC LIQUID CRYSTAL PHASES | MERCK PATENT GmbH (DE) | 1988-03-09 | — | — | EP | disclosed |
| EP-0235219-A1 | BICYCLO-OCTANE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-09-09 | — | — | EP | disclosed |
| WO-1987005013-A2 | SMECTIC LIQUID CRYSTAL PHASES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-08-27 | — | — | WO | disclosed |
| WO-1987001113-A1 | BICYCLO-OCTANE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1987-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958819-B2 | Compounds for optically active devices | PDE6C, ALDH1A2, PDE6A | ACE2 1348/4885FFAR4 3949/4885FFAR1 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.